[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100546970":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":23,"locations":29,"responsibleParty":48,"collaborators":10,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":10,"eligibilityCriteria":55,"healthyVolunteers":52,"sex":56,"minAge":57,"maxAge":10,"enrollmentInfo":58,"targetDuration":10,"studyType":61,"phases":10,"briefSummary":62,"conditions":63,"keywords":10,"overallStatus":32,"whyStopped":10,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Mayo Clinic","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Observational",null,"Patients complete surveys\u002Fquestionnaires, undergo skin measurement with the VISIA CA device, undergo facial skin photography, and attend consultations with an aesthetician on study.",[13],"Other: Non-Interventional Study",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"Non-Interventional Study","Non-interventional study",[9],[20],{"name":21,"affiliation":5,"role":22},"Leila M. Tolaymat, M.D.","PRINCIPAL_INVESTIGATOR",[24],{"name":25,"role":26,"phone":27,"phoneExt":10,"email":28},"Clinical Trials Referral Office","CONTACT","855-776-0015","mayocliniccancerstudies@mayo.edu",[30],{"facility":31,"status":32,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Mayo Clinic in Florida","RECRUITING","Jacksonville","Florida","32224-9980","United States","US",{"type":39,"coordinates":40},"Point",[41,42],-81.65565,30.33218,{"lat":42,"lon":41},[45,47],{"name":46,"role":26,"phone":27,"phoneExt":10,"email":28},"Clinical Trials Referral Office, M.D.",{"name":21,"role":22,"phone":10,"phoneExt":10,"email":10},{"type":49,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100546970","enhancing-skin-appearance-and-quality-of-life-in-breast-cancer-survivors-on-aromatase-inhibitor-therapy-100546970",false,"NCT06401889","Enhancing Skin Appearance and Quality of Life in Breast Cancer Survivors on Aromatase Inhibitor Therapy","Inclusion Criteria:\n\n* \\* Female ≥ 18 years\n\n  * Postmenopausal women suitable to receive aromatase inhibitor as per physician's discretion\n  * Histologically confirmed adenocarcinoma of the breast stage 0-III with estrogen receptor (ER) and\u002For progesterone receptor (PR) positive per American Society of Clinical Oncology (ASCO)\u002F College of American Pathologists (CAP) guideline and any human epidermal growth factor receptor 2 (HER2)\n  * Patients must not have received any prior chemotherapy or endocrine therapy for their current breast cancer. Patients who received tamoxifen or raloxifene or another agent for prevention of breast cancer may be included\n  * Patients willing to avoid any facial procedures including facials, neurotoxin injections, fillers, or lasers during study period\n  * Willing and able to provide consent\n\nExclusion Criteria:\n\n* \\* Patients who have previously taken AIs\n\n  * Patients using prescription tretinoin, neurotoxin injections, fillers, facial lasers, microneedling, or facials within 6 months of study consent","FEMALE","18 Years",{"count":59,"type":60},35,"ESTIMATED","OBSERVATIONAL","This study evaluates changes in skin quality and self-esteem among breast cancer patients who are initiating aromatase inhibitor therapy.",[64,65,66,67,68,69,70],"Anatomic Stage 0 Breast Cancer AJCC v8","Anatomic Stage I Breast Cancer AJCC v8","Anatomic Stage II Breast Cancer AJCC v8","Anatomic Stage III Breast Cancer AJCC v8","Breast Adenocarcinoma","Estrogen Receptor-Positive Breast Carcinoma","Progesterone Receptor-Positive Breast Carcinoma","2026-05-18",{"date":73,"type":74},"2026-05-19","ACTUAL",{"date":76,"type":74},"2024-07-19",{"date":78,"type":60},"2027-07-19",{"name":5,"class":6},1]